Summary of COVID-19 FX06 studies
Hide extended summaries
RCT 49 patients with COVID-19-associated ARDS showing no significant effect of FX06 on vascular leakage or mortality.
Aug 2023, Critical Care, https://ccforum.biomedcentral.com/articles/10.1186/s13054-023-04616-1, https://c19p.org/guerin2
1. Guérin et al., FX06 to rescue SARS-CoV-2-induced acute respiratory distress syndrome: a randomized clinical trial
49 patient FX06 ICU RCT: 10% higher mortality (p=1).RCT 49 patients with COVID-19-associated ARDS showing no significant effect of FX06 on vascular leakage or mortality.
Aug 2023, Critical Care, https://ccforum.biomedcentral.com/articles/10.1186/s13054-023-04616-1, https://c19p.org/guerin2
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.